ReviewFrontiers in physiology2018
The Role of Neuropeptide Y in Cardiovascular Health and Disease.
Review in Frontiers in physiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
113 citing papers in PubMed, 1 synthesis or guideline pooled it, 196 citations in OpenAlex.
- Chronic Stress A Potential Suspect Zero of Atherosclerosis: A Systematic Review.Frontiers in cardiovascular medicine · 2021Pooled it
- Plasma neuropeptide Y levels and adverse clinical outcomes after acute ischaemic stroke.European journal of neurology · 2025Trial
- Neuropeptide Y deficiency perturbs L-type calcium and outward potassium currents leading to ventricular arrhythmogenesis in mice.The Journal of clinical investigation · 2026Article
- Future GLP-1 receptor co-agonists and their cardiac effects.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Neurocardiology: Brain-Heart Interactions in the Heart.MedComm · 2026Review
- Neuropeptide Y in cancer metastasis and chemoresistance.Neuropeptides · 2026Review
- Integrative gene target mapping, RNA sequencing, in silico molecular docking, ADMET profiling and molecular dynamics simulation study of marine derived molecules for type 1 diabetes mellitus.Molecular diversity · 2026Article
- Neuropeptide Y promotes myocardial fibrosis post myocardial infarction reperfusion through Neuropeptide Y receptor type 1.Clinical and experimental medicine · 2026Article
- The Apelin-APJ Axis in Heart Failure: Mechanistic Insights, Clinical Evidence, and Translational Challenges.Cardiovascular drugs and therapy · 2026Review
- Neurogenic heterotopic ossification: from molecular mechanisms to clinical treatment.Journal of orthopaedic translation · 2026Review
- Neuropeptide Y as a Neuro-Immune Checkpoint in Cancer.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026Review
- Genetic variability in the leptin-melanocortin pathway and its role in weight loss.Molecular metabolism · 2026Review
- Participation of neuropeptide Y and its receptors in leukotriene formation in the pig inflamed endometrium.Scientific reports · 2026Article
- Multimodal, device-based therapeutic targeting of the cardiovascular autonomic nervous system.Nature reviews. Cardiology · 2026Review
- The FMRFamide-like peptide FLP-11 regulates the production and secretion of the TGF-β-like protein DAF-7 during Caenorhabditis elegans larval development.Scientific reports · 2026Article
- Neural Regulation of Cardiac Arrhythmias: From the Brain-Heart Axis to Emerging Precision Therapies.Research (Washington, D.C.) · 2026Review
- Targeting Neuropeptide Y: Novel Approaches to the Treatment of Cardiovascular and Haematological Disorders.Cardiovascular & hematological disorders drug targets · 2026Review
- The Association of Neuropeptide Y with the Presence and Frequency of Ventricular Premature Beats.Current cardiology reviews · 2026Article
- Selective Receptor Modulation by Truncated Neuropeptide Y (3-36) Dissociates Vasoconstriction from Neuroprotection in Experimental Glaucoma.Molecular neurobiology · 2025Article
- A novel approach to the prevention and management of cardiovascular diseases: targeting brain-heart axis.European journal of medical research · 2025Review
53 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Neuropeptide Y (NPY) is an abundant sympathetic co-transmitter, widely found in the central and peripheral nervous systems and with diverse roles in multiple physiological processes. In the cardiovascular system it is found in neurons supplying the vasculature, cardiomyocytes and endocardium, and is involved in physiological processes including vasoconstriction, cardiac remodeling, and angiogenesis. It is increasingly also implicated in cardiovascular disease pathogenesis, including hypertension, atherosclerosis, ischemia/infarction, arrhythmia, and heart failure. This review will focus on the physiological and pathogenic role of NPY in the cardiovascular system. After summarizing the NPY receptors which predominantly mediate cardiovascular actions, along with their signaling pathways, individual disease processes will be considered. A thorough understanding of these roles may allow therapeutic targeting of NPY and its receptors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.